Surrozen Inc
SRZN12.280USD
+0.300+2.50%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
105.24MMarket Cap
LossP/E TTM
More Details of Surrozen Inc Company
Surrozen, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a range of organs and tissues. The Company is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a current focus on severe liver and eye diseases. Its two lead product candidates include SZN-043 and SZN-413. SZN-043 is the first development candidate using Surrozen’s SWEETS technology. It is developing SZN-043 for severe liver diseases, initially focusing on alcohol-associated hepatitis. It has completed Phase I a clinical trial in patients with chronic liver disease and healthy volunteers. SZN-413 is a bi-specific antibody targeting Fzd4-mediated Wnt signaling designed using Surrozen’s SWAP technology. SZN-413 is being developed for the treatment of retinal vascular-associated diseases.
Company Info
Ticker SymbolSRZN
Company nameSurrozen Inc
IPO dateNov 23, 2020
CEOMr. Craig C. Parker
Number of employees40
Security typeOrdinary Share
Fiscal year-endNov 23
Address171 Oyster Point Blvd
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94080
Phone16504752820
Websitehttps://www.surrozen.com
Ticker SymbolSRZN
IPO dateNov 23, 2020
CEOMr. Craig C. Parker
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Yang Li, Ph.D.
Mr. Yang Li, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
13.74K
+3.00%
Mr. Charles O. Williams
Mr. Charles O. Williams
Chief Financial Officer, Chief Operating Officer, Corporate Secretary
Chief Financial Officer, Chief Operating Officer, Corporate Secretary
9.38K
+4.45%
Dr. Mary Haak-Frendscho, Ph.D.
Dr. Mary Haak-Frendscho, Ph.D.
Independent Director
Independent Director
2.34K
--
Dr. Shao-Lee Lin, M.D., Ph.D.
Dr. Shao-Lee Lin, M.D., Ph.D.
Independent Director
Independent Director
2.34K
--
Dr. Anna Berkenblit, M.D.
Dr. Anna Berkenblit, M.D.
Independent Director
Independent Director
2.34K
--
Mr. Christopher Y. Chai
Mr. Christopher Y. Chai
Independent Director
Independent Director
2.34K
--
Dr. Mace Rothenberg, M.D.
Dr. Mace Rothenberg, M.D.
Independent Director
Independent Director
2.34K
--
Mr. Eric H. Bjerkholt
Mr. Eric H. Bjerkholt
Independent Director
Independent Director
--
--
Dr. David J. Woodhouse, Ph.D.
Dr. David J. Woodhouse, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Craig C. Parker
Mr. Craig C. Parker
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Yang Li, Ph.D.
Mr. Yang Li, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
13.74K
+3.00%
Mr. Charles O. Williams
Mr. Charles O. Williams
Chief Financial Officer, Chief Operating Officer, Corporate Secretary
Chief Financial Officer, Chief Operating Officer, Corporate Secretary
9.38K
+4.45%
Dr. Mary Haak-Frendscho, Ph.D.
Dr. Mary Haak-Frendscho, Ph.D.
Independent Director
Independent Director
2.34K
--
Dr. Shao-Lee Lin, M.D., Ph.D.
Dr. Shao-Lee Lin, M.D., Ph.D.
Independent Director
Independent Director
2.34K
--
Dr. Anna Berkenblit, M.D.
Dr. Anna Berkenblit, M.D.
Independent Director
Independent Director
2.34K
--
Mr. Christopher Y. Chai
Mr. Christopher Y. Chai
Independent Director
Independent Director
2.34K
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Aug 19
Updated: Tue, Aug 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Column Group LP
17.50%
StemPoint Capital LP
8.01%
VR Adviser, LLC
7.39%
RA Capital Management, LP
7.03%
5AM Ventures
3.62%
Other
56.46%
Shareholders
Shareholders
Proportion
The Column Group LP
17.50%
StemPoint Capital LP
8.01%
VR Adviser, LLC
7.39%
RA Capital Management, LP
7.03%
5AM Ventures
3.62%
Other
56.46%
Shareholder Types
Shareholders
Proportion
Venture Capital
41.38%
Investment Advisor
12.58%
Hedge Fund
8.45%
Investment Advisor/Hedge Fund
5.38%
Corporation
3.57%
Endowment Fund
2.16%
Research Firm
1.33%
Individual Investor
0.52%
Other
24.64%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
62
5.88M
68.70%
+2.83M
2025Q1
63
5.89M
68.82%
+2.82M
2024Q4
60
2.77M
85.24%
-182.72K
2024Q3
64
2.45M
79.78%
-789.59K
2024Q2
65
2.67M
92.21%
-363.75K
2024Q1
62
1.51M
74.09%
-612.70K
2023Q4
67
1.55M
75.80%
-569.05K
2023Q3
69
1.40M
67.10%
-482.07K
2023Q2
98
1.37M
65.24%
-770.64K
2023Q1
99
1.41M
68.52%
-723.50K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Column Group LP
1.50M
17.52%
+689.68K
+85.14%
Mar 31, 2025
StemPoint Capital LP
240.83K
2.81%
-109.75K
-31.31%
Mar 31, 2025
VR Adviser, LLC
632.93K
7.39%
+632.93K
--
Mar 31, 2025
RA Capital Management, LP
679.13K
7.93%
+396.55K
+140.33%
Mar 31, 2025
5AM Ventures
310.00K
3.62%
+310.00K
--
Mar 31, 2025
Stonepine Capital Management, LLC
285.78K
3.34%
+148.58K
+108.30%
Mar 31, 2025
Access Industries, Inc.
306.00K
3.57%
+306.00K
--
Mar 24, 2025
Vivo Capital, LLC
260.00K
3.04%
+260.00K
--
Mar 31, 2025
Samsara BioCapital, LLC
241.40K
2.82%
+241.40K
--
Mar 31, 2025
Nantahala Capital Management, LLC
229.53K
2.68%
+33.50K
+17.09%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Dec 12, 2023
Merger
15→1
Dec 12, 2023
Merger
15→1
Dec 12, 2023
Merger
15→1
Dec 12, 2023
Merger
15→1
Date
Type
Ratio
Dec 12, 2023
Merger
15→1
Dec 12, 2023
Merger
15→1
Dec 12, 2023
Merger
15→1
Dec 12, 2023
Merger
15→1
